Panacea Biotec share news, announcements and annual reports
NSE: PANACEABIOBSE: 531349Pharmaceuticals & BiotechnologySmall Cap
Panacea Biotec Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1996 on BSE, Apr 1996 on NSE
Last close ₹327.75up ₹14.50 (4.63%)BSE ₹326.65
Share price at the NSE close on 2 Nov 2026. Previous close ₹313.25.
2 Nov: open ₹315.50, high ₹329.75, low ₹314.95
52-week range of traded prices to 2 Nov 2026
₹292.40Low, 30 Mar 2026₹647.00High, 9 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,007 Cr1,088th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −0.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹11 crore of one-off items, the largest of them in the quarter to Dec 2025.
- −2.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −3.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 48,28047.7% delivered
Panacea Biotec share news and announcements
875 announcements, routine notices left out, newest first. Page 13 of 18.
Apr 2016
Mar 2016
26 Mar · Updates
Credit Rating for Long Term bank facilities of Rs.1202.88 cr. and Short term bank facilities of Rs. 61.97 cr. Pursuant to the provisions of Regulation 30 read with clause 3 of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that on the basis of recent developments including operational and financial performance of the Company for financial year 2014-15 and financial year 2015-16 (9 months), Credit Analysis & Research Ltd. (CARE) has revised credit rating with respect to the Company s Bank Facilites, as under:- 1. Long Term Bank Facilities - From CARE D (Single D) to CARE B- (Single B-) 2. Short Term Bank Facilities - From CARE D (Single D) to CARE A4 (A Four) In this regard, it may be noted that the CARE B rating indicates that Instruments with this rating are considered to have high risk of default regarding timely servicing of financial obligations. The modifiers (+) or (-) as the case may be reflect the comparative standing within the category. Similarly, the CARE A4 rating indicates that the Instruments with this rating are considered to have minimal degree of safety regarding timely payment of financial obligations. Such instruments carry very high credit risk and are susceptible to default.
Feb 2016
Jan 2016
Dec 2015
Nov 2015
Oct 2015
3 Oct · Disclosure of Voting Pattern - Clause 35A
Sep 2015
24 Sep · Corrigendum
Aug 2015
21 Aug · Management
Dr. Aditya Narain Saksena, Non Executive Independent Director of the Company has resigned from the directorship of the Company vide his letter dated August 20, 2015 due to his ill health and that of his wife and accordingly he ceased to be director of the Company w.e.f. the close of business hours on August 20, 201513 Aug · Results
Jul 2015
May 2015
28 May · Board meeting
Apr 2015
Mar 2015
Feb 2015
2 Feb · Board meeting
To inter-alia, consider and approve the Unaudited Financial Results (Provisional) for the quarter ended December 31, 2014.
Jan 2015
8 Jan · Disclosure of Voting Pattern - Clause 35A
Dec 2014
12 Dec · Legal
Exchange had sought clarification from Panacea Biotec Limited with respect to a news item captioned "Germany bans 80 generic drugs for insufficient trials". The Company has clarified that "Panacea Biotec through its local entity Panacea Biotec Germany GmbH is proceeding in line with the instructions of the Germany s drug regulator and is taking appropriate steps to overcome the situation. The overall impact of this action on the Company s financials is expected to be immaterial".11 Dec · Legal
Exchange has sought clarification from Panacea Biotec Limited with respect to recent news item captioned "Germany bans 80 generic drugs for insufficient trials". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.9 Dec · Board meeting
Board of Directors of the Company had, in its meeting held on December 09, 2014, inter-alia, decided, subject to the approval of shareholders, for issue of 0.5% Non-convertible Cumulative Redeemable Preference Shares of Rs.10/- each at par to the promoters and their relatives by way of conversion of existing unsecured loans / public deposits from them and/or fresh contribution in cash, aggregating to Rs.34.30 Crore towards promoter s contribution as per the terms of CDR-LOA dated 09.09.2014, subject to CDR Lenders agreeing to consider such Preference Shares as the promoters contribution. The Board had also decided that an Extra-ordinary General Meeting of the Company will be held on January 06, 2015.
Nov 2014
Oct 2014
31 Oct · Results